Patents by Inventor Linda Lemieux
Linda Lemieux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148784Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: November 8, 2023Publication date: May 9, 2024Applicant: Astellas Institute for Regenerative MediceInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilnr
-
Patent number: 11850261Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: GrantFiled: October 9, 2019Date of Patent: December 26, 2023Assignee: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20220049217Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells am molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described hemin are useful for treating retinal degenerative diseases.Type: ApplicationFiled: March 29, 2021Publication date: February 17, 2022Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20210060062Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: October 9, 2019Publication date: March 4, 2021Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20200113938Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: October 9, 2019Publication date: April 16, 2020Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Patent number: 10485829Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: GrantFiled: November 17, 2010Date of Patent: November 26, 2019Assignee: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20190062703Abstract: The present invention provides improved methods For producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: ApplicationFiled: August 27, 2018Publication date: February 28, 2019Applicant: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Patent number: 10077424Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: GrantFiled: April 16, 2014Date of Patent: September 18, 2018Assignee: Astellas Institute for Regenerative MedicineInventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20150086512Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: ApplicationFiled: April 16, 2014Publication date: March 26, 2015Applicant: Advanced Cell Technology, Inc.Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20130149284Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.Type: ApplicationFiled: November 17, 2010Publication date: June 13, 2013Applicant: Advanced Cell Technlogy, Inc.Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20110274662Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: ApplicationFiled: October 10, 2008Publication date: November 10, 2011Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner